www.urologiepropraxi.cz / Urol. praxi. 2023;24(3):140-145 / UROLOGIE PRO PRAXI 145 PŘEHLEDOVÉ ČLÁNKY Imunoterapie u nádorů ledvin LITERATURA 1. Bukavina L, Bensalah K, Bray F, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022;82(5):529542. doi: 10.1016/j.eururo.2022.08.019. Epub 2022 Sep 10. PMID: 36100483. 2. Krejčí D, Pehalová L, Talábová A, et al. Novotvary 2018 ČR: Současné epidemiologické trendy novotvarů v České republice [Internet]. 2018. [cit. 2023-02-26]. ISSN 1210-857X. Available from: https://www.uzis.cz/res/f/008352/novotvary2018.pdf. 3. Moch H, Amin MB, Bernea DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs – Part A: Renal, Penile, and Testicular Tumours. European Urology [Internet]. 2022;82(5):458-468. [cit. 2023-03-16]. ISSN 03022838. Available from: doi:10.1016/j. eururo.2022.06.016. 4. Magee DE, Helstrom E, Kutikov A. The role of cytoreductive nephrectomy in the immuno-oncological therapy era. Curr Opin Urol. 2023;33(2):136-141. doi: 10.1097/ MOU.0000000000001077. Epub 2023 Jan 9. PMID: 36710594. 5. Studentova H, Rusarova N, Ondruskova A. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: a Case Series and Review of the Literature. Curr Oncol. 2022;29(8):5475-5488. doi: 10.3390/curroncol29080433. PMID: 36005171; PMCID: PMC9406807. 6. Escudier B, Porta C, Schmidinger M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706720. doi: 10.1093/annonc/mdz056. PMID: 30788497. 7. Bosma NA, Warkentin MT, Gan CL, et al. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Open Sci. 2022;37:14-26. doi: 10.1016/j.euros.2021.12.007. PMID: 35128482; PMCID: PMC8792068. 8. Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442. doi: 10.3389/fimmu.2022.964442. PMID: 36177034; PMCID: PMC9513184. 9. Escudier B, Porta C, Schmidinger, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2019;30(5):706720. [cit. 2023-02-26]. ISSN 09237534. Dostupné z: doi:10.1093/ annonc/mdz056. 10. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine [Internet]. 2021;385(8):683-694. [cit. 2023-03-02]. ISSN 0028-4793. Available from z: doi:10.1056/ NEJMoa2106391. 11. Pal SK, Uzzo S, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. The Lancet [online]. 2022;400(10358):1103-1116. [cit. 2023-03-16]. ISSN 01406736. Available from: doi:10.1016/S0140-6736(22)01658-0. 12. Motzer RJ, Haas NB, Donskov F, et al. PROTECT investigators. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13. PMID: 28902533; PMCID: PMC6018511. 13. Motzer RJ, Ravaud A, Patard JJ, et al. Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. 2018;73(1):6268. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28. PMID: 28967554; PMCID: PMC6684251. 14. Martini DJ, Liu Y, Shabto JM, et al. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2020;25(3):e484-e491. doi: 10.1634/theoncologist.2019-0578. Epub 2019 Dec 5. PMID: 32162798; PMCID: PMC7066702. 15. Kiss I, Adámková Krákorová D, Andrašina T, et al. Modrá kniha České onkologické společnosti, 28. aktualizace, Brno, Masarykův onkologický ústav. 2022. ISBN: 978-80-86793-53-5. 16. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683-694. 17. Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo- -controlled, phase 3 trial. Lancet Oncol. 2022;23(9):1133-1144. 18. George D, Jonasch E. Systemic therapy of advanced clear cell renal carcinoma [Internet]. [cit. 2023-02-26]. Available from: https://www.uptodate.com/contents/systemic-therapy-of-advanced-clear-cell-renal-carcinoma?search=ipilimumab%20nivolumab&source=search_result&selectedTitle=5~91&usage_type=default&display_rank=5. 19. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine [Internet]. 373. 2015 [cit. 2023-02-26]. ISSN 0028-4793. Available from: http:// www.nejm.org/doi/10.1056/NEJMoa1510665. 20. Rini B, Plicmack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine [Internet]. 2019;380(12). [cit. 2020-07-28]. DOI: 10.1056/NEJMoa1816714. ISSN 00284793. Available from: http://www.nejm.org/doi/10.1056/ NEJMoa1816714. 21. Poprach A, Lakomý R. New treatment options for metastatic renal cell carcinoma [Internet]. 20-24 [cit. 2023-0226]. ISSN 18024475. Dostupné z: doi:10.36290/xon.2022.004. 22. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine [Internet]. 2021;384(9):829-841. [cit. 2023-03-16]. ISSN 0028-4793. Available from: doi:10.1056/NEJMoa2026982. 23. Motzer R, Alekseev B, Rha SY, et al. CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384(14):1289-1300. 24. Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus Pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;23:228-238. 25. Motzer RJ, Tannir NM, McDermott DF, et al. CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. PMID: 29562145; PMCID: PMC5972549. 26. Motzer RJ, Penkov K, Hannen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine [Internet]. 2019;380(12):1103-1115 [cit. 2023-03-16]. ISSN 0028-4793. Available from: doi:10.1056/ NEJMoa1816047. VĚRNÝM ČTENÁŘŮM SUPPLEMENTUM ZAZNĚLO NA 25. ROČNÍKU MORAVSKÉHO UROLOGICKÉHO SYMPOZIA 15.–16. 5. 2023 / Hotel Sepetná ZAZNĚLO NA 25. ROČNÍKU Moravského urologického sympozia 15.–16. 5. 2023 / Hotel Sepetná www.solen.cz | 2023
RkJQdWJsaXNoZXIy NDA4Mjc=